4-(Methoxymethyl)-3,5-dimethylisoxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(Methoxymethyl)-3,5-dimethylisoxazole
• 英文别名: 4-(methoxymethyl)-3,5-dimethyl-1,2-oxazole
• 化学式: C₇H₁₁NO₂
• mdl: MFCD01314792
• 分子量: 141.17
• InChiKey: FKAPBBUQCHSTCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• PYRROLIDINYL SULFONE RORGAMMA MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191483A1

  公开（公告）日：2015-07-09

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ活性的方法和治疗受疾病或紊乱困扰的主体中是有用的，例如，主体将从调节RORγ活性中获益的自免疫和/或炎症紊乱。
• Methods of Treating Obesity and Metabolic Disorders
  申请人：Hofgen Norbert

  公开号：US20090143392A1

  公开（公告）日：2009-06-04

  The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.

  本发明涉及使用PDE10抑制剂pyrido [3,2-e] pyrazines治疗或预防肥胖症、2型糖尿病、代谢综合征或葡萄糖不耐症的方法。本发明还涉及减少体脂肪或体重的方法。
• Pyrido[3,2-e]pyrazines, their use as inhibitors of phospohodiesterase 10, and processes for preparing them
  申请人：Hofgen Norbert

  公开号：US20090239874A1

  公开（公告）日：2009-09-24

  The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.

  本发明涉及吡啶并[3,2-e]吡嗪、其制备方法、含有该化合物的制药组合物以及将其作为磷酸二酯酶10的抑制剂的活性化合物，用于治疗哺乳动物包括人类的疾病，这些疾病可以通过使用本发明的化合物来抑制中枢神经系统中的磷酸二酯酶10活性来影响。具体而言，本发明涉及神经逻辑和精神障碍的治疗，例如精神病和包括认知缺陷症状的障碍。
• 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20090036444A1

  公开（公告）日：2009-02-05

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性，是一种预防或治疗丙型肝炎的药剂。
• Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
  申请人：Hofgen Norbert

  公开号：US20080027064A1

  公开（公告）日：2008-01-31

  The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.

  本发明涉及吡啶并[3,2-e]吡嗪类化合物、其制备方法、包含这些化合物的制药组合物以及这些化合物的制药用途。该化合物是磷酸二酯酶10的抑制剂，可用作治疗哺乳动物包括人类的疾病的活性成分，这些疾病可以通过使用本发明的化合物抑制中枢神经系统中的磷酸二酯酶10活性来影响。具体而言，本发明涉及治疗神经和精神障碍，例如包括认知缺陷症状的精神病和障碍的治疗。